# A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053

> **NCT06229548** · PHASE1 · COMPLETED · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 39 (actual)

## Conditions studied

- Hyperlipemia

## Interventions

- **DRUG:** SYH2053
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06229548
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-08
- **Primary completion:** 2024-12-23
- **Final completion:** 2025-03-25
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06229548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06229548, "A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06229548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*